Biohaven Insiders Bet $33 Million on a Turnaround

Biohaven logo alongside pills, syringe, and mask underscores pipeline focus and growth outlook. Key Points Substantial share purchases by top executives show a powerful alignment of their personal financial interests with those of everyday shareholders. Management has executed a decisive strategic pivot, focusing capital on its most promising clinical assets to drive future growth and enhance value. The company's streamlined pipeline features multiple high-potential drug candidates with significant dat ...